MX361741B - Tratamientos médicos a base de anamorelina. - Google Patents

Tratamientos médicos a base de anamorelina.

Info

Publication number
MX361741B
MX361741B MX2017002825A MX2017002825A MX361741B MX 361741 B MX361741 B MX 361741B MX 2017002825 A MX2017002825 A MX 2017002825A MX 2017002825 A MX2017002825 A MX 2017002825A MX 361741 B MX361741 B MX 361741B
Authority
MX
Mexico
Prior art keywords
anamorelin
medical treatments
cancer
therapeutically effective
treatments based
Prior art date
Application number
MX2017002825A
Other languages
English (en)
Spanish (es)
Other versions
MX2017002825A (es
Inventor
Lu Ming
Mann William
Friend John
Polvino William
Allen Suzan
Duus Elizabeth
Giorgino Ruben
Baroni Enrico
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX361741(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MX2017002825A publication Critical patent/MX2017002825A/es
Publication of MX361741B publication Critical patent/MX361741B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2017002825A 2014-09-04 2015-08-28 Tratamientos médicos a base de anamorelina. MX361741B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Publications (2)

Publication Number Publication Date
MX2017002825A MX2017002825A (es) 2017-09-28
MX361741B true MX361741B (es) 2018-12-14

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002825A MX361741B (es) 2014-09-04 2015-08-28 Tratamientos médicos a base de anamorelina.

Country Status (44)

Country Link
US (5) US9675600B2 (enExample)
EP (2) EP3188599B1 (enExample)
JP (3) JP6356907B2 (enExample)
KR (3) KR102234319B1 (enExample)
CN (5) CN109172575A (enExample)
AP (1) AP2017009772A0 (enExample)
AR (1) AR103118A1 (enExample)
AU (1) AU2015312231B2 (enExample)
BR (1) BR112017003552A2 (enExample)
CA (1) CA2959158A1 (enExample)
CL (1) CL2017000494A1 (enExample)
CO (1) CO2017003263A2 (enExample)
CR (1) CR20170121A (enExample)
CY (1) CY1122746T1 (enExample)
DK (1) DK3188599T3 (enExample)
DO (1) DOP2017000055A (enExample)
EA (1) EA035578B1 (enExample)
EC (1) ECSP17019893A (enExample)
ES (1) ES2761777T3 (enExample)
GE (2) GEP20186939B (enExample)
HR (1) HRP20192345T1 (enExample)
HU (1) HUE046894T2 (enExample)
IL (1) IL250692B (enExample)
JO (1) JO3541B1 (enExample)
LT (1) LT3188599T (enExample)
MA (1) MA40607B1 (enExample)
MD (1) MD4710C1 (enExample)
ME (1) ME03597B (enExample)
MX (1) MX361741B (enExample)
MY (1) MY187167A (enExample)
NI (1) NI201700024A (enExample)
PE (1) PE20171109A1 (enExample)
PH (1) PH12017500392B1 (enExample)
PL (1) PL3188599T3 (enExample)
PT (1) PT3188599T (enExample)
RS (1) RS59751B1 (enExample)
SG (1) SG11201701567UA (enExample)
SI (1) SI3188599T1 (enExample)
SV (1) SV2017005400A (enExample)
TN (1) TN2017000040A1 (enExample)
TW (1) TWI639429B (enExample)
UA (1) UA120765C2 (enExample)
UY (1) UY36286A (enExample)
WO (1) WO2016036598A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
LT3188599T (lt) 2014-09-04 2019-12-10 Helsinn Healthcare Sa Medicininio gydymo būdai, pagrįsti anamorelinu
WO2020037151A1 (en) 2018-08-16 2020-02-20 Aimmune Therapeutics, Inc. Peanut oral immunotherapy with maintenance dose
CN113891722A (zh) 2018-12-20 2022-01-04 爱沐疗法公司 用于漏服剂量的花生口服免疫疗法给药计划表
CN113966229A (zh) 2019-05-10 2022-01-21 爱沐疗法公司 用于改善花生过敏患者的生活质量的方法
EP4021419A1 (en) 2019-08-30 2022-07-06 Helsinn Healthcare SA Methods of manufacturing anamorelin tablets having improved stability
US20240139176A1 (en) * 2019-10-24 2024-05-02 Toray Industries, Inc. Methods of treating or preventing cachexia
TW202327596A (zh) * 2021-09-17 2023-07-16 瑞士商赫爾辛保健公司 於厭食/惡病體質患者針對患者自述結果判定及提供臨床有意義改善之方法
WO2025004650A1 (ja) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 中高年者の疲労感を軽減するための剤及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
EP1660117A2 (en) * 2003-08-06 2006-05-31 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
EP1735055A1 (en) 2004-03-30 2006-12-27 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
CN103772483A (zh) 2004-06-29 2014-05-07 赫尔辛医疗股份公司 （3r）－1－（2－甲基丙氨酰－d－色氨酰）－3－（苯甲基）－3－哌啶羧酸1,2,2－三甲基酰肼的晶形
MX2009008561A (es) * 2007-02-13 2010-01-15 Helsinn Therapeutics Us Inc Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
JP2015517452A (ja) 2012-05-25 2015-06-22 ラクオリア創薬株式会社 無酸症を治療するためのグレリン受容体アゴニスト
LT3188599T (lt) 2014-09-04 2019-12-10 Helsinn Healthcare Sa Medicininio gydymo būdai, pagrįsti anamorelinu

Also Published As

Publication number Publication date
US20170296526A1 (en) 2017-10-19
AU2015312231A1 (en) 2017-03-23
CN107205389A (zh) 2017-09-26
US10278964B2 (en) 2019-05-07
KR20170047372A (ko) 2017-05-04
CY1122746T1 (el) 2021-03-12
ECSP17019893A (es) 2017-05-31
CR20170121A (es) 2017-07-17
UA120765C2 (uk) 2020-02-10
SV2017005400A (es) 2017-04-20
JO3541B1 (ar) 2020-07-05
HRP20192345T1 (hr) 2020-03-20
ES2761777T3 (es) 2020-05-21
NZ729673A (en) 2023-09-29
CN113577073A (zh) 2021-11-02
MD4710C1 (ro) 2021-04-30
MY187167A (en) 2021-09-07
CO2017003263A2 (es) 2017-07-28
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
JP2021080281A (ja) 2021-05-27
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
JP6356907B2 (ja) 2018-07-11
TWI639429B (zh) 2018-11-01
CL2017000494A1 (es) 2017-09-15
JP7044918B2 (ja) 2022-03-30
US10894041B2 (en) 2021-01-19
RS59751B1 (sr) 2020-02-28
IL250692B (en) 2019-05-30
EP3188599B1 (en) 2019-10-02
UY36286A (es) 2016-02-29
MD4710B1 (ro) 2020-09-30
AU2015312231B2 (en) 2017-10-19
KR20180085047A (ko) 2018-07-25
EP3590338A3 (en) 2020-03-18
JP2018154655A (ja) 2018-10-04
TN2017000040A1 (en) 2018-07-04
WO2016036598A1 (en) 2016-03-10
US9675600B2 (en) 2017-06-13
US20160067236A1 (en) 2016-03-10
CN113577074A (zh) 2021-11-02
ME03597B (me) 2020-07-20
US20190175574A1 (en) 2019-06-13
PL3188599T3 (pl) 2020-06-01
CN107375285A (zh) 2017-11-24
AR103118A1 (es) 2017-04-19
US20210093627A1 (en) 2021-04-01
CN109172575A (zh) 2019-01-11
JP2017526695A (ja) 2017-09-14
EP3590338A2 (en) 2020-01-08
US20240024303A1 (en) 2024-01-25
PH12017500392A1 (en) 2017-07-17
MD20170025A2 (ro) 2017-07-31
SI3188599T1 (sl) 2020-02-28
LT3188599T (lt) 2019-12-10
MA40607B1 (fr) 2019-11-29
JP6923486B2 (ja) 2021-08-18
PH12017500392B1 (en) 2018-08-31
GEAP201814459A (en) 2018-09-10
PT3188599T (pt) 2020-01-15
KR102234319B1 (ko) 2021-04-01
EP3188599A4 (en) 2017-10-11
KR101881264B1 (ko) 2018-07-23
TW201613587A (en) 2016-04-16
KR20210035923A (ko) 2021-04-01
PE20171109A1 (es) 2017-08-07
KR102307275B1 (ko) 2021-09-30
IL250692A0 (en) 2017-04-30
CA2959158A1 (en) 2016-03-10
US11723902B2 (en) 2023-08-15
SG11201701567UA (en) 2017-03-30
AP2017009772A0 (en) 2017-02-28
EP3188599A1 (en) 2017-07-12
MX2017002825A (es) 2017-09-28
NI201700024A (es) 2017-07-18
HUE046894T2 (hu) 2020-04-28
BR112017003552A2 (pt) 2017-12-05
DOP2017000055A (es) 2017-08-15

Similar Documents

Publication Publication Date Title
MX361741B (es) Tratamientos médicos a base de anamorelina.
MX2021002322A (es) Nuevos metodos.
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2017005875A (es) Metodos para tratar enfermedades oculares.
TWD196868S (zh) 超音波治療手持件
EA201791199A1 (ru) Способ лечения болезни альцгеймера
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
AU2018326364A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
MX390722B (es) Tratamiento de resistencia a diureticos.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones
UA113183C2 (xx) Спосіб лікування адикції
GT201700041A (es) Tratamientos médicos a base de anamorelina
EA201890019A1 (ru) Способ профилактики недостаточности трансплантата у реципиента
AR102494A1 (es) Métodos para tratar enfermedades oculares
Fabiny Ask the doctor. I recently took antibiotics to treat an oral infection and as a result developed a vaginal yeast infection. Can I treat it myself, and what are the most effective options?
RU2015109209A (ru) Способ количественной оценки зубочелюстно-лицевых аномалий
EA201991866A1 (ru) Комбинированная терапия
EA201692163A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
UA116484U (uk) Cпосіб лікування артеріальної гіпертензії з метаболічним синдромом
UA115063U (xx) Спосіб лікування собак із больовим синдромом при панкреатиті

Legal Events

Date Code Title Description
FG Grant or registration